NF PROTOCOL 108: A Phase II Study of Binimetinib in Children and Adults with NF1 associated Plexiform Neurofibromas (PNOC010)
Are you eligible to participate in this study?
You may be eligible for this study if you meet the following criteria:
-
Conditions: Nf1 Associated Plexiform Neurofibromas
-
Age: Between 1 - 100 Years
-
Gender: Male or Female
-
Other Inclusion Criteria:
1. Patients must have EITHER the clinical diagnosis of NF1 OR have a constitutional NF1 mutation 2. Patients must have plexiform neurofibroma(s) that are progressive 3. Patients only eligible if complete resection of a plexiform neurofibroma with acceptable morbidity is not feasible, or if a subject with surgical option refuses surgery.
You may not be eligible for this study if the following are true:
-
1. Chronic treatment with systemic steroids or another immunosuppressive agent. 2. Evidence of an active optic glioma or other low-grade glioma, requiring treatment with chemotherapy or radiation therapy. 3. Patients with malignant glioma, malignant peripheral nerve sheath tumor, or other malignancy requiring treatment in the last 12 months.
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.